Citigroup
ANVS icon

Citigroup’s Annovis Bio ANVS Stock Holding History

Citigroup’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$123 Buy
55
+54
+5,400% +$148 ﹤0.01% 5599
2025
Q4 		$3 Buy
+1
New +$3 ﹤0.01% 5894
2024
Q1 		– Sell
-11,197
Closed -$209K – 5628
2023
Q4 		$209K Buy
+11,197
New +$99.3K ﹤0.01% 3893
2023
Q1 		– Sell
-6
Closed -$81 – 5471
2022
Q4 		$81 Hold
6
– – ﹤0.01% 5647
2022
Q3 		$0 Buy
6
+1
+20% +$13 ﹤0.01% 5796
2022
Q2 		$0 Sell
5
-70
-93% -$765 ﹤0.01% 6207
2022
Q1 		$1K Buy
75
+70
+1,400% +$1.01K ﹤0.01% 6139
2021
Q4 		$0 Buy
+5
New +$129 ﹤0.01% 5798
2021
Q2 		– Sell
-303
Closed -$8K – 6107
2021
Q1 		$8K Buy
+303
New +$6.48K ﹤0.01% 5743

Other funds holding ANVS

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Citigroup's ANVS Position: Q1 2026 in Review

Citigroup increased its Annovis Bio (ANVS) stake by 5,400% in Q1 2026, buying an estimated $148 and bringing the position to 55 shares worth $123. The position accounts for ﹤0.01% of the portfolio, ranked #5599.

Citigroup first reported a position in ANVS in Q1 2021 and has held it in 9 quarters since. The position peaked at $209K in Q4 2023. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

  • Citigroup held 55 shares of Annovis Bio worth $123 as of Q1 2026.
  • Citigroup bought 54 Annovis Bio shares in Q1 2026, an estimated $148.
  • Annovis Bio made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5599 holding.
  • Citigroup first reported a position in Annovis Bio in Q1 2021 and has held it in 9 quarters since.
  • Citigroup's Annovis Bio position peaked at $209K in Q4 2023.
  • 56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.